AXIAL SPONDYLOARTHRITIS · HLA-B27 ASSOCIATED · BAMBOO SPINE
A physician-led, laboratory-verified treatment programme designed to reduce chronic spinal inflammation, restore functional mobility and slow structural progression — tailored to the individual biology, disease stage and clinical profile of each AS patient.
Request Medical ConsultationAbout the Condition
Ankylosing Spondylitis (AS) is a chronic inflammatory condition that primarily affects the axial skeleton — the spine and sacroiliac joints. Over time, persistent inflammation can lead to new bone formation and progressive spinal fusion, resulting in reduced mobility, chronic pain and significant functional impairment.
AS is strongly associated with the HLA-B27 genetic marker and typically presents in early adulthood, between ages 20 and 40. Men are affected approximately two to three times more frequently than women, though the condition is increasingly recognised in both sexes. The disease course is highly variable — some patients experience intermittent flares, while others face relentless structural progression.
Standard pharmacological management relies on NSAIDs, TNF inhibitors and IL-17 blockers. While these suppress symptoms, they do not address the underlying immune dysregulation or halt new bone formation. Our programme targets these deeper biological mechanisms — aiming to modify the disease trajectory rather than manage its surface.
Axial AS (Predominantly Spinal)
The classic presentation, with inflammation centred on the sacroiliac joints and spine. Progressive syndesmophyte formation may lead to partial or complete spinal fusion. Morning stiffness lasting over 30 minutes and nocturnal pain that improves with movement are hallmark features.
Peripheral AS (Joint Involvement)
In addition to axial symptoms, peripheral joints — hips, knees, shoulders — are affected. Enthesitis (inflammation at tendon and ligament insertion points) is common. This pattern often leads to broader functional limitation beyond spinal mobility alone.
AS with Extra-articular Manifestations
Up to 40% of AS patients develop complications beyond the musculoskeletal system. Anterior uveitis (acute eye inflammation) is the most common, affecting approximately 25–30% of patients. Inflammatory bowel disease and cardiac involvement may also occur.
Non-radiographic Axial Spondyloarthritis (nr-axSpA)
Early-stage disease where clinical symptoms and MRI findings are present but structural damage is not yet visible on standard X-ray. This stage represents a critical therapeutic window — intervention before irreversible bone formation occurs offers the greatest potential for long-term disease modification.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates diagnosis, disease stage, inflammatory markers, structural damage and overall clinical profile.
We do not offer a cure for ankylosing spondylitis. Our programme is designed to target the biological mechanisms driving inflammation, immune dysregulation and pathological bone formation — with the clinical objective of reducing disease activity, improving functional capacity and slowing structural progression.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2017 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
36
AS patients treated since 2013
76%
measurable functional stabilisation on BASDAI at 3–6 months
−2.1 pts
average BASDAI score change at 6 months — vs. expected +0.4 pts natural progression
64%
sustained functional stability with average 2 years of follow-up
82%
showed improvement in one or more measured domains
72%
retained independence in basic activities of daily living (ADL) at 12 months
Joint & spinal function (spinal mobility, peripheral joint function, enthesitis resolution, morning stiffness)
78%
Inflammation (CRP/ESR reduction, imaging signs of inflammation, uveitis flare frequency)
71%
Systemic symptoms (nocturnal pain, sleep disruption, systemic fatigue)
74%
Quality of life (mood, daily activity tolerance, work capacity)
68%
2–6 weeks
Initial inflammatory response
2–5 months
Clinically meaningful change
1–2 years onward
Long-term stability — continuous monitoring
Important: Outcomes depend on disease duration, degree of structural damage, HLA-B27 status, baseline inflammatory markers and individual biological response. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“Eight years of waking up at 3 or 4 am from back pain. Stiff for two hours every morning, barely able to tie my shoes. After the treatment in Warsaw I started sleeping through to 6. The morning stiffness went from two hours to about twenty minutes. My rheumatologist measured improved spinal mobility at the last check-up. First time the numbers went in the right direction since diagnosis.”
Patient
Ankylosing Spondylitis · Germany
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationPatient Cases
Documented treatment outcomes recorded by the BioCells Medical team after personalised regenerative medicine protocols.
The BioCells Program
Our AS programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's inflammatory profile, structural status and clinical priorities.
Minimally invasive administration
Treatment is delivered by intravenous infusion or targeted local injection using specialised medical systems — not surgical instruments.
No general anaesthesia
The entire protocol is performed under local anaesthesia or without anaesthesia at all. No respiratory risk, no recovery period from sedation.
No risk of immune rejection
MSCs are immunoprivileged: they express low levels of HLA-I, lack HLA-II and carry a minimal risk of rejection whether the protocol is autologous or allogeneic. Allogeneic MSC protocols do not require immunosuppression.
Targets the underlying biology, not just symptoms
Rather than suppressing symptoms with lifelong medication, our protocol targets the immune dysregulation, entheseal inflammation and pathological ossification that drive AS progression.
Complements existing medication
Our programme is compatible with NSAIDs, TNF inhibitors, IL-17 blockers and other current standard medications. Patients do not need to discontinue existing treatment before commencing our protocol.
Patients from around the world
We work with patients from around the world. Airport transfers, accommodation, visa support and multilingual coordination are included in every treatment programme.
What It Is
MSCs are multipotent regenerative cells with proven immunomodulatory and anti-inflammatory properties. They are among the most extensively studied cell types in regenerative medicine, with documented efficacy in autoimmune and inflammatory conditions across thousands of clinical applications.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 3-5 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are then expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Ankylosing Spondylitis
In AS, persistent inflammation at the entheses and sacroiliac joints triggers a destructive cycle: chronic immune activation leads to tissue damage, which in turn stimulates abnormal new bone formation. MSCs interrupt this cycle at its source — reducing the inflammatory load, recalibrating immune signalling and creating conditions that slow the progression from inflammation to ankylosis.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific diagnosis, disease stage, biological markers and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current BASDAI/BASFI status, imaging findings, medical history and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation — including MRI, X-ray, blood markers (CRP, ESR, HLA-B27) and current medication regimen. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Airport transfers, accommodation and visa support are included in the programme for international patients.
Structured rehabilitation sessions with our specialist, focused on spinal mobility restoration, postural correction and functional strengthening. Protocols are adapted to your current range of motion and disease stage. Available at our clinic or remotely coordinated with your local physiotherapy team.
Your dedicated coordinator monitors disease activity, inflammatory markers and functional status. A medical-grade wearable bracelet supports continuous health tracking. Clinical guidance and protocol adjustments are provided based on your recovery data regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of AS patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's status has changed — including active uveitis flare or intercurrent infection — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated rehabilitation specialist
monitors spinal mobility, pain levels and overall functional capacity
Personalised rehabilitation programme
focused on spinal extension, postural correction and joint mobility maintenance
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in disease activity
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Immunological recalibration and structural stabilisation are gradual biological processes. The post-treatment period requires consistent monitoring, structured rehabilitation and clinical oversight to support and sustain the therapeutic response.
Get Started
If you or someone you care about has been diagnosed with ankylosing spondylitis, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, current disease activity and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
